Summary: Reasons for performing study: Maggot debridement therapy is a long‐established tool to promote wound healing. Objectives: To describe and assess the results of this technique in equids with various lesions. Methods: Retrospective analysis performed on cases in which, depending on clinical case, type, size and location of the wound, maggots were applied either in direct or indirect contact with the wound. Results: Treated cases (n = 41) included horses with foot pathology (n = 9), laceration of the limbs (n = 15), other soft tissue abscesses or wounds (n = 6), fistulous withers (n = 5), other musculoskeletal infection (n = 2) and dehiscence of the linea alba (n = 4). In 5 cases, a second maggot application was necessary to reach the desired level of wound healing. In 38 cases a favourable outcome was reached in less than one week. In one individual with a sequestrum, healing was uneventful after its removal. In 2 other horses, squamous cell carcinoma and melanoma were involved in chronic infected wounds and complete healing was not achieved because of recurrence of underlying tumours. Some discomfort was recorded in 7 individuals between 24 and 72 h of treatment. Conclusions: Maggot debridement therapy can be recommended in equids for debridement and enhanced healing and its potent antibacterial action. Maggot debridement therapy is not recommended on wounds invaded with a tumour and if bone sequestration is suspected. Potential relevance: Maggot debridement therapy can be an integral part of modern wound care in equids.

Objective—To compare accuracy of 2 methods for injection of the podotrochlear bursa in horses. Design—Observational study. Animals—17 French Standardbreds. Procedure—In each horse, contrast medium was injected into the podotrochlear bursa of 1 foot by use of a distal palmar approach with the needle inserted parallel to the sole (DPPS) and into the podotrochlear bursa of the other foot by use of a distal palmar approach to the navicular position (DPNP). Podotrochlear bursa injection was evaluated by means of radiographic examination in all horses and postmortem examination in 6. Results—Contrast medium was successfully injected into the podotrochlear bursa in 6 of 16 feet in which the DPPS method was used and 14 of 17 feet in which the DPNP method was used; these results were significantly different. Failure was attributed to contrast medium invading the distal interphalangeal joint, contrast medium pooling palmar to the deep digital flexor tendon, contrast medium located in the podotrochlear bursa and the distal interphalangeal joint, contrast medium located in the podotrochlear bursa and the area palmar to the deep digital flexor tendon, and an inability to inject contrast medium despite adequate needle placement. Conclusions and Clinical Relevance—Results suggest that the DPNP technique can be used successfully for injection into the podotrochlear bursa in horses. However, radiographic assessment should be used to confirm that material was injected into the bursa. (J Am Vet Med Assoc 2005;226:1524–1528)

Osteochondrosis (OC(D)) is a juvenile osteo-articular disorder affecting several mammalian species. In horses, OC(D) is considered as a multifactorial disease and has been described as a focal disruption of endochondral ossification leading to the development of osteoarticular lesions. Nevertheless, OC(D) physiopathology is poorly understood. Affected horses may present joint swelling, stiffness and lameness. Thus, OC(D) is a major concern for the equine industry. Our study was designed as an integrative approach using omics technologies for the identification of constitutive defects in epiphyseal cartilage and/or subchondral bone associated with the development of primary lesions to further understand OC(D) pathology. This study compared samples from non-affected joints (hence lesion-free) from OC(D)-affected foals (n = 5, considered predisposed samples) with samples from OC-free foals (n = 5) considered as control samples. Consequently, results are not confounded by changes associated with the evolution of the lesion, but focus on altered constitutive molecular mechanisms. Comparative proteomics and micro computed tomography analyses were performed on predisposed and OC-free bone and cartilage samples. Metabolomics was also performed on synovial fluid from OC-free, OC(D)-affected and predisposed joints. Two lesion subtypes were identified: OCD (lesion with fragment) and OC (osteochondral defects). Modulated proteins were identified using omics technologies (2-DE proteomics) in cartilage and bone from affected foals compare to OC-free foals. These were associated with cellular processes including cell cycle, energy production, cell signaling and adhesion as well as tissue-specific processes such as chondrocyte maturation, extracellular matrix and mineral metabolism. Of these, five had already been identified in synovial fluid of OC-affected foals: ACTG1 (actin, gamma 1), albumin, haptoglobin, FBG (fibrinogen beta chain) and C4BPA (complement component 4 binding protein, alpha). This study suggests that OCD lesions may result from a cartilage defect whereas OC lesions may be triggered by both bone and cartilage defects, suggesting that different molecular mechanisms responsible for the equine osteochondrosis lesion subtypes and predisposition could be due to a defect in both bone and cartilage. This study will contribute to refining the definition of OC(D) lesions and may improve diagnosis and development of therapies for horses and other species, including humans.